CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.33
−4.31%Nov 2, 2026, 12:00 UTC
Climb Bio announced that members of its executive team will participate in the upcoming Guggenheim Partners LLC 3rd Annual Healthcare Innovation Conference.
Source:Oct 24, 2026, 23:30 UTC
Climb Bio, Inc. presented initial Phase 2 PrisMN data showing that 200 mg of budoprutug demonstrated B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in patients with primary membranous nephropathy.
Source:Oct 23, 2026, 20:01 UTC
Climb Bio and Beijing Mabworks Biotech announced clinical data for CLYM116/MIL116 showing more than 90% free APRIL suppression sustained through 12 weeks and an approximately 70% reduction in Gd-IgA1 at 12 weeks.
Source:Oct 2, 2026, 13:30 UTC
Climb Bio announced it will present new data on CLYM116 and budoprutug at the American Society of Nephrology (ASN) Kidney Week 2026, including preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation.
Source:Sep 3, 2026, 17:52 UTC
Climb Bio Inc. released preliminary data from its ongoing Phase 1 trial of CLYM116 for IgA nephropathy and announced updated strategic plans for the treatment.
Source:Aug 6, 2026, 00:00 UTC
Climb Bio, Inc. reported a net loss of $13.5 million for Q2 2026, compared to a net loss of $8.7 million in Q2 2025.
Jun 17, 2026, 16:23 UTC
Climb announced a North American distribution partnership with Ivanti to expand access to Ivanti's Autonomous Endpoint Management solution.
Source: